[1]黄冬琴,吴 蔓.不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓形成的疗效[J].医学信息,2020,33(10):122-123.[doi:10.3969/j.issn.1006-1959.2020.10.034]
　HUANG Dong-qin,WU Man.Therapeutic Effect of Different Doses of Urokinase via Catheter Thrombolysis on Lower Limb Deep Vein Thrombosis[J].Medical Information,2020,33(10):122-123.[doi:10.3969/j.issn.1006-1959.2020.10.034]
点击复制

不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓形成的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年10期
页码:
122-123
栏目:
临床研究
出版日期:
2020-05-15

文章信息/Info

Title:
Therapeutic Effect of Different Doses of Urokinase via Catheter Thrombolysis on Lower Limb Deep Vein Thrombosis
文章编号:
1006-1959（2020）10-0122-02
作者:
黄冬琴; 吴 蔓
（江西省宜春市第二人民医院普外科，江西 宜春 336000）
Author(s):
HUANG Dong-qin; WU Man
(General Surgery,the Second People’s Hospital of Yichun City,Yichun 336000,Jiangxi,China)
关键词:
尿激酶; 溶栓; 下肢深静脉; 血栓
Keywords:
Urokinase; Thrombolysis; Deep veins of lower extremities; Thrombosis
分类号:
R543.6
DOI:
10.3969/j.issn.1006-1959.2020.10.034
文献标志码:
A
摘要:
目的 分析不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓形成的疗效。方法 回顾分析2018年2月~2019年2月在我院在进行溶栓治疗的120例患者临床资料，依据尿激酶用药剂量、频次分为A（38例）、B（40例）、C（42例）三组。A组12.5万U/次，1次/d；B组12.5万U/次，2次/d；C组25万U/次，2次/d。比较三组治疗后凝血指标[凝血酶原时间（PT）、纤维蛋白原（Fg）、D一二聚体（DD）]、血栓溶解率、术后血栓静脉评分以随访6个月复发率、并发症发生情况。结果 治疗后三组PT、Fg、DD比较，差异有统计学意义（P＜0.05），且尿激酶用量与凝血指标变化幅度有关（P＜0.05）；术后三组血栓溶解率随尿激酶用量增加而逐渐升高，血栓静脉评分随尿激酶用量逐渐降低（P＜0.05），A组分别与B组、C组比较，差异有统计学意义（P＜0.05），B组与C组比较，差异无统计学意义（P＞0.05）；随访6个月，A、B、C组并发症发生率分别为2.63%、5.00%、7.14%，三组比较差异无统计学意义（P＞0.05）。结论 不同剂量尿激酶经导管溶栓治疗下肢深静脉血栓疗效存在一定差异，尿激酶每日用量为25 U可实现较高的血栓溶解率和低风险，而增加每日给药频次，可提高血栓溶解率。
Abstract:
Objective To analyze the therapeutic effect of different doses of urokinase through catheter thrombolysis on lower limb deep vein thrombosis.Methods The clinical data of 120 patients undergoing thrombolytic therapy in our hospital from February 2018 to February 2019 were retrospectively analyzed and divided into A (38 cases), B (40 cases), and C ( 42 cases) Three groups. Group A: 125,000 U/time, 1 time/d; Group B: 125,000 U/time, 2 times/d; Group C: 250,000 U/time, 2 times/d. Compare the coagulation indexes [prothrombin time (PT), fibrinogen (Fg), D-dimer (DD)], thrombolysis rate, postoperative thrombus venous score for 6 months follow-up relapse rate, The occurrence of complications.Results After treatment, the difference of PT, Fg and DD between the three groups was statistically significant(P<0.05), and the amount of urokinase was related to the change range of coagulation index(P<0.05); The rate increased gradually with the increase of urokinase dosage, and the thrombosis vein score gradually decreased with the urokinase dosage, the difference was statistically significant (P<0.05). Group A was compared with groups B and C, the difference was statistically significant(P<0.05),there was no statistically significant difference between group B and group C(P>0.05); after 6 months of follow-up, the incidence of complications in groups A, B, and C were 2.63%, 5.00%, and 7.14%, respectively,there was no statistically significant difference between the three groups (P>0.05).Conclusion There are some differences in the efficacy of different doses of urokinase through catheter thrombolysis for lower limb deep vein thrombosis. The daily dosage of urokinase of 25 U can achieve higher thrombolysis rate and lower risk, while increasing the daily frequency of administration can increase thrombosis dissolution rate.

参考文献/References:

[1]王深明,武日东.下肢深静脉血栓形成治疗指南与实践[J].中国实用外科杂志,2015,35(12):1264-1266.[2]黄永周,黄桂林,李志刚,等.大剂量尿激酶治疗下肢深静脉血栓形成疗效观察[J].临床和实验医学杂志,2015,10(5):349-350.[3]郭方军.手术取栓与药物溶栓治疗急性髂股型下肢深静脉血栓形成的疗效比较[J].中国现代普通外科,2017,26(8):8-10.[4]鉴涛,陈鋆,秦委委.导管直接溶栓治疗急性下肢深静脉血栓形成的疗效分析[J].实用医学杂志,2014(6):1006-1007.

相似文献/References:

[1]宋俊燕,张 毅.重组人尿激酶原在急性ST段抬高型心肌梗死中的 疗效及并发症分析[J].医学信息,2018,31(11):133.[doi:10.3969/j.issn.1006-1959.2018.11.042]
　SONG Jun-yan,ZHANG Yi.Therapeutic Efficacy and Complications of Recombinant Human Pro-urokinase in Acute ST-elevation Myocardial Infarction[J].Medical Information,2018,31(10):133.[doi:10.3969/j.issn.1006-1959.2018.11.042]
[2]杨涌涛,金 戈,李 鑫,等.脑梗死静脉溶栓后出血转化与脂质代谢异常的 相关性研究[J].医学信息,2019,32(14):75.[doi:10.3969/j.issn.1006-1959.2019.14.024]
　YANG Yong-tao,JIN Ge,LI Xin,et al.Correlation between Hemorrhagic Transformation and Abnormal Lipid Metabolism after Venous Thrombolysis in Patients with Cerebral Infarction[J].Medical Information,2019,32(10):75.[doi:10.3969/j.issn.1006-1959.2019.14.024]
[3]姜 博,刘 艳.FPG和HbA1c对急性脑梗死合并2型糖尿病患者静脉溶栓效果的影响[J].医学信息,2020,33(08):118.[doi:10.3969/j.issn.1006-1959.2020.08.037]
　JIANG Bo,LIU Yan.Effects of FPG and HbA1c on the Efficacy of Intravenous Thrombolysis in Patients with Acute Cerebral Infarction and Type 2 Diabetes[J].Medical Information,2020,33(10):118.[doi:10.3969/j.issn.1006-1959.2020.08.037]
[4]张玉香.脑蛋白水解物联合尿激酶治疗急性脑卒中的效果[J].医学信息,2020,33(11):114.[doi:10.3969/j.issn.1006-1959.2020.11.035]
　ZHANG Yu-xiang.Effect of Brain Protein Hydrolysate Combined with Urokinase on Acute Stroke[J].Medical Information,2020,33(10):114.[doi:10.3969/j.issn.1006-1959.2020.11.035]
[5]徐 迪.AngioJet血栓抽吸术与置管溶栓术治疗深静脉血栓临床疗效和凝血功能的比较[J].医学信息,2023,36(08):120.[doi:10.3969/j.issn.1006-1959.2023.08.025]
　XU Di.Comparison of Clinical Efficacy and Coagulation Function Between AngioJet Thrombus Aspiration and Catheter Thrombolysis in the Treatment of Deep Venous Thrombosis[J].Medical Information,2023,36(10):120.[doi:10.3969/j.issn.1006-1959.2023.08.025]
[6]刘 宏,何明方,吴政俊.静脉溶栓前脑白质疏松程度与AIS患者术后HT及短期预后的关系[J].医学信息,2024,37(01):145.[doi:10.3969/j.issn.1006-1959.2024.01.025]
　LIU Hong,HE Ming-fang,WU Zheng-jun.Relationship Between the Degree of Leukoaraiosis Before Intravenous Thrombolysis and Postoperative HT, Short-term Prognosis in AIS Patients[J].Medical Information,2024,37(10):145.[doi:10.3969/j.issn.1006-1959.2024.01.025]
[7]童玲玲,林燕妮,朱健清,等.发病4.5~6 h急性脑梗死尿激酶溶栓疗效和安全性分析[J].医学信息,2024,37(07):98.[doi:10.3969/j.issn.1006-1959.2024.07.018]
　TONG Ling-ling,LIN Yan-ni,ZHU Jian-qing,et al.Analysis of Efficacy and Safety on Urokinase Thrombolysis in Acute Cerebral Infarction at 4.5-6 h of Onset[J].Medical Information,2024,37(10):98.[doi:10.3969/j.issn.1006-1959.2024.07.018]

更新日期/Last Update: 2020-05-15